Help available for those at risk of severe COVID
Those at risk of developing severe COVID-19 have a new weapon in their arsenal.
The Federal government has announced it placed oral antiviral treatment Legevrio on the Pharmaceutical Benefits Scheme (PBS) on March 1.
Lagevrio is a five-day treatment suitable for adults who test positive to COVID and are at risk of developing severe disease.
The subsidy is available to people are at risk due to several factors including an existing medical condition and age. Patients must not have been hospitalised and do not require oxygen supplementation.
A course of Lagevrio is available for $6.80 concession, or $42.50 for general patients.
2 comments
2 comments
Also
Patients eligible to access LAGEVRIO through the PBS include:2
1. Patients 65 years or older with two additional high-risk factors* for developing severe diseasePatients
2. 75 years or older with one additional high-risk factor* for developing severe disease Moderately to severely immunocompromised people irrespective of vaccination status,
and Aboriginal and Torres Strait Islander people aged 50 years or older with two additional high-risk factors* for developing severe disease.
All medicines carry the risk of side-effects.
LAGEVRIO (molnupiravir) - Merck Sharp & Dohme (Australia) Pty Ltd
In clinical trials, the most common adverse events associated with LAGEVRIO treatment were diarrhoea, nausea, and dizziness.4
The Therapeutic Goods Administration (TGA) has granted provisional approval for
PAXLOVID (nirmatrelvir + ritonavir) - Pfizer Australia Pty Ltd